arrow
H

Heather H. Cheng

Fred Hutchinson Cancer Center
H指数:43
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression Reflect Prostate Cancer Phenotypes in Metastatic Disease

循环肿瘤细胞突触素和雄激素受体表达反映转移性前列腺癌的表型

2026-10-120
OAAI
Prostate Cancer, Version 3.2026

前列腺癌,版本3.2026,NCCN肿瘤学临床实践指南

2025-11-012
PRE
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study

膀胱癌亚型组织学患者中经尿道膀胱肿瘤切除术与根治性膀胱切除术病理结果的一致性:一项回顾性队列研究

2025-11-010
PRE
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Niraparib和abiraterone acetate联合prednisone治疗HRR缺陷型转移性去势敏感前列腺癌:一项随机III期试验

2025-10-070
OAAI
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency

多西他赛和卡铂诱导治疗伴DNA同源重组修复缺陷的转移性去势抵抗性前列腺癌患者的2期研究结果

2025-05-230
PRE
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2025-02-070
PRE
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings

基于PET的TheraP资格及VISION试验合格患者中接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者的结局:18F-FDG显像不一致结果的重要性

2024-11-141
PRE
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

3个月和7个月的前列腺特异性抗原水平可作为转移性激素敏感性前列腺癌总生存期的预后指标: SWOG S1216的结果,这是一项雄激素剥夺加Orteronel或比卡鲁胺的3期随机试验

2024-10-012
OA
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing

适应社会生态模型以解决黑人参与前列腺癌基因检测的差异

2024-09-180
OAAI
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

同时发生的BRCA2/SPOP突变可预测转移性去势抵抗性前列腺癌中特殊的聚 (ADP-核糖) 聚合酶抑制剂敏感性

2024-08-015
PRE
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
2024-05-173
OAAI
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy

前列腺癌的挽救治疗: AUA/ASTRO/SUO指南第二部分: 原发性根治性前列腺切除术后非转移性生化复发的治疗

2024-04-014
PRE
Prostate Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
2024-04-0124
OA